CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)
- PMID: 19063694
- DOI: 10.1517/14712590802614538
CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)
Abstract
Background: Early clinical trials of HER2/neu-derived peptide vaccines indicate that they may be useful for preventing recurrence in breast cancer patients rendered disease-free after standard-of-care therapy. An effective vaccination strategy will probably require stimulation of T helper (Th) cells. AE37 is an HER2/neu-derived peptide that has been modified to enhance antigen-specific stimulation of Th cells by linkage of the Ii-Key moiety of the MHC class II-associated invariant chain (Ii protein).
Objective: To review the literature regarding the role of a Th response in immunotherapy with a focus on this novel HER2/neu-derived AE37 peptide.
Results/conclusion: Improved immuno-genicity of the AE37 Ii-key hybrid peptide has been demonstrated in animal models, ex vivo patient cells, and, most recently, in a Phase I clinical trial in breast cancer patients. Future clinical trials incorporating AE37 into a peptide vaccine strategy are warranted.
Similar articles
-
Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.Clin Cancer Res. 2010 Jul 1;16(13):3495-506. doi: 10.1158/1078-0432.CCR-10-0085. Epub 2010 May 13. Clin Cancer Res. 2010. PMID: 20466887 Clinical Trial.
-
CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.Vaccine. 2012 Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3. Vaccine. 2012. PMID: 22386748 Review.
-
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.Cancer Immunol Immunother. 2007 May;56(5):601-13. doi: 10.1007/s00262-006-0213-z. Epub 2006 Sep 8. Cancer Immunol Immunother. 2007. PMID: 16960693 Free PMC article.
-
Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain.Int J Cancer. 2007 Nov 1;121(9):2031-2041. doi: 10.1002/ijc.22936. Int J Cancer. 2007. PMID: 17634957
-
AE37: a novel T-cell-eliciting vaccine for breast cancer.Expert Opin Biol Ther. 2011 Nov;11(11):1543-50. doi: 10.1517/14712598.2011.616889. Epub 2011 Sep 6. Expert Opin Biol Ther. 2011. PMID: 21895539 Review.
Cited by
-
Potential association factors for developing effective peptide-based cancer vaccines.Front Immunol. 2022 Jul 27;13:931612. doi: 10.3389/fimmu.2022.931612. eCollection 2022. Front Immunol. 2022. PMID: 35967400 Free PMC article.
-
Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer.Cancers (Basel). 2021 Jan 6;13(2):173. doi: 10.3390/cancers13020173. Cancers (Basel). 2021. PMID: 33419051 Free PMC article. Review.
-
Clinical applications of mouse models for breast cancer engaging HER2/neu.Integr Cancer Sci Ther. 2016;3(5):593-603. doi: 10.15761/ICST.1000210. Epub 2016 Oct 28. Integr Cancer Sci Ther. 2016. PMID: 28133539 Free PMC article.
-
Recent advances in the development of breast cancer vaccines.Breast Cancer (Dove Med Press). 2014 Oct 14;6:159-68. doi: 10.2147/BCTT.S38428. eCollection 2014. Breast Cancer (Dove Med Press). 2014. PMID: 25339848 Free PMC article. Review.
-
Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines.J Transl Med. 2012 Jul 31;10:154. doi: 10.1186/1479-5876-10-154. J Transl Med. 2012. PMID: 22849661 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
